ClinicalTrials.gg
RecruitingNCT07301203Updated Dec 24, 2025

Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects

A Phase 1 interventional study of CPD704 Inhalation Suspension and CPD704 placebo in Healthy and Healthy Participants, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension in healthy Chinese adult subjects.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension administered via nebulization in healthy Chinese adult subjects.

02

Conditions studied

  • Healthy
  • Healthy Participants

Keywords

  • Phase I Study of CPD704 in Healthy Subjects
  • CPX201-I-01
03

In context

Lead sponsor

Beijing Tide Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject can communicate well with the researchers, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written form;
  2. Healthy subjects aged 18-55 years (including the boundary value, subject to the time of signing the informed consent form), male or female;
  3. (BMI) within the range of 19 \~ 28 kg/m2 (including the critical value), male weight ≥ 50 kg, female weight ≥ 45 kg;
  4. The subject has no plans to give birth, sperm or egg donation from the signing of the informed consent form to 90 days after medication, and voluntarily takes medically approved measures (including his partner)

Exclusion criteria

Exclusion Criteria:

  1. Patients who have taken any clinical trial drugs or participated in any drug clinical trial within 3 months before signing the ICF, or participated in other medical research activities, and are not suitable for participating in this trial as judged by the investigator;
  2. Previous or combined with the following diseases, cardiovascular disease [such as heart failure (such as fluid retention and edema), unstable ischemic heart disease, congestive heart failure poor control of coronary artery disease, myocardial infarction, long syndrome history, etc.], respiratory, renal, neurological, endocrine, immune, skin, gastrointestinal (such as gastrointestinal ulcers or gastrointestinal bleeding, etc.), liver or blood system and other diseases/abnormal history, the investigators judge that their participation in this trial may affect the safety of subjects or affect the analysis of study results;
  3. Patients with the following mental illness: 1) Uncontrolled/unstable major depressive disorder (MDD) or other serious mental disorders (such as schizophrenia, bipolar disorder or other serious mood or anxiety disorders) within 2 years before screening; 2) Suicide attempt or suicidal behavior 30 times before screening; 3) Suicidal ideation corresponding to Columbia-Suicide Severity Rating Scale (C-SSRS) category 4 or 5 in the past 30;
  4. Known , immune reaction or intolerance to CPD704 Inhalation Suspension or any of the in the drug product (polysorbate 80, sodium chloride, sodium citrate dihydrate, disodium edetate, sodium hydroxide or hydrochloric acid) and/or unsuitable for treatment with CPD704 Inhalation Suspension;
  5. Long-term oral drugs can not be stopped or suffering from gastric ulcer, gastritis affecting oral activated charcoal, or allergic to activated charcoal;
  6. Patients with severe infection, trauma or major surgery before signing the ICF, or planning to undergo surgery during the trial;
  7. Use of any (except influenza vaccine) within 28 days before signing the ICF or plan to receive vaccines during the study;
  8. Blood loss or blood donation of more than 400 mL within 3 months before signing the ICF (excluding female menstrual blood loss), or intend to donate blood during the trial or within 1 month after the end of the trial;
  9. Smokers or those who smoke more than 5 cigarettes per day within 3 months before signing the ICF, or those who cannot comply with the provisions of prohibiting smoking during the trial, or those who test positive for urine cotinine;
  10. Pulmonary ventilation function test (FEV1) measured value/FEV1 predicted value ≤ 80% or forced vital capacity (FVC) ≤ 80% of predicted value or any other abnormalities;
  11. Use of any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 28 days before signing the ICF; or use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before signing the ICF. If the half-life of concomitant drugs is increased, the required time interval should be at least 5 half-lives of the drug;
  12. Excessive consumption of tea, coffee or caffeinated beverages (an average of more than 8 cups per day, 250 mL per cup) within 6 months before signing the ICF;
  13. Consumption of any grapefruit, caffeine-containing beverages or foods (such as grapefruit juice, coffee, strong tea, chocolate, caffeine-containing carbonated beverages, cola, cocoa, etc.) within 48 hours before the first dose;
  14. Those who have special requirements for diet and cannot abide by the unified diet;
  15. Unwilling or unable to tolerate multiple venipuncture or difficult venous blood sampling or a history of fainting;
  16. Previous history of drug abuse/drug use, or drug abuse screening (including tetrahydrocannabinolic acid, morphine, ketamine, methamphetamine, benzodiazepine, cocaine) results were positive;
  17. Regular drinking within 6 months before signing the ICF [i.e., women drink more than 14 standard units of alcohol per week, men drink more than 21 standard units of alcohol per week (1 standard unit contains 14 g of alcohol, such as 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine)] or can not abstain from alcohol during the trial; or positive breath alcohol test;
  18. The results of physical examination, vital signs examination, , laboratory tests (blood routine, blood biochemistry, coagulation function, thyroid function, urine routine, stool routine, etc.), chest X-ray, abdominal B ultrasound examination during the screening period are judged by the study doctor as abnormal and clinically significant;
  19. Abnormal ECG findings during the screening period, such as bradycardia or tachycardia (heart rate \< 50 bpm or > 100 bpm), QTc prolongation (QTcF interval ≥ 450 ms in males and ≥ 470 ms in females, corrected according to Fridericia's formula), arrhythmia, etc., and clinically significant as judged by the investigator;
  20. Patients with positive results of any test of surface antigen (HbsAg), virus antibody (HCV-Ab), treponema pallidum antibody (Syphilis TP) and test (HIV-Ag/Ab) during the screening period;
  21. Pregnant or lactating women, or positive blood pregnancy test results;
  22. Unwilling or unable to correctly use the nebulizer according to the nebulizer instructions Inhalation of drugs or nebulizer use training failed;
  23. Any other condition that, in the opinion of the investigator, would make participation in the study inappropriate.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Other
    SAD 0.5mg

    For SAD 0.5mg cohort will enroll 2 subjects who will receive CPD704 once. 0.5 mg per administration

    Drug: CPD704 Inhalation Suspension

  • Other
    SAD 1.5mg

    The SAD 1.5mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant.1.5 mg per administration.

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

  • Other
    SAD 3mg

    This group will include exploratory studies onmetabolite identification, excretion pathways, and excretion quantification(conducted in Cycle 1) as well as anactivated charcoal gastrointestinal absorption blockade study(conducted in Cycle 2). A total of12 subjects will be enrolled (10:2 =CPD704 treatment group: placebo group), Each subject will receive a single 3 mg dose per cycle via oral inhalation.

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

  • Other
    SAD 6mg

    The SAD 6mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,6 mg per administration.

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

  • Other
    SAD 9mg

    The SAD 9mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,9 mg per administration.

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

  • Other
    SAD 12mg

    The SAD 12mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,12 mg per administration..

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

  • Other
    MAD 1.5mg

    Each cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation. Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses).1.5 mg per administration.

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

  • Other
    MAD 3mg

    Each cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation. Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses) . 3 mg per administration.

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

  • Other
    MAD 6mg

    Each cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation. Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses). Each dose:6mg.

    Drug: CPD704 Inhalation Suspension · Other: CPD704 placebo

Interventions

  • DrugCPD704 Inhalation Suspension

    This trial employs standard jet nebulizers (air-compression nebulizers) for oral inhalation administration。

  • OtherCPD704 placebo

    The placebo is administered via standard jet nebulizer (air-compression nebulizer) for oral inhalation

06

What researchers measure

Primary outcomes

  1. Safety outcomes

    Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0.

    Time frame: From the date of informed consent signature until Day 7 for SAD group(Day 14 for SAD 3mg group) and Day 11 for MAD Group.

Secondary outcomes

  1. Pharmacokinetic (PK) endpoints

    Plasma concentrations of CPD704 following nebulization of CPD704 inhalation suspension

    Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after first dose

  2. Pharmacokinetic (PK) endpoints

    Cmax of CPD704 following nebulized administration of CPD704 inhalation suspension

    Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose

  3. Pharmacokinetic (PK) endpoints

    Time to reach peak plasma concentration (Tmax) of CPD704 following nebulized administration of CPD704 inhalation suspension

    Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose

  4. Pharmacokinetic (PK) endpoints

    Area under the plasma concentration-time curve from time zero to time t (AUC0-t) of CPD704 following nebulized administration of CPD704 inhalation suspension

    Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose

  5. Pharmacokinetic (PK) endpoints

    t1/2 of CPD704 after nebulization of CPD704 inhalation suspension

    Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose

  6. Pharmacokinetic (PK) endpoints

    PK profile of CPD704 inhalation suspension following activated charcoal blockade (including AUC0-∞, AUC0-t, Cmax and other parameters)

    Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose

Other outcomes

  1. QTcF interval

    Evaluation of QTcF interval prolongation potential following single-dose administration of CPD704 inhalation suspension in healthy adult volunteers

    Time frame: From 60 minutes prior to first dose until 12 hours of first dose.

  2. Metabolites and excretion pathways

    Preliminary investigation of CPD704 metabolites in humans and primary excretion pathways, including cumulative excretion rates of the parent drug and metabolites (if applicable) in urine and feces

    Time frame: only applicable for SAD 3mg cohort, From 60 minutes prior to first dose until 48Hours of last dose.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jun 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 24, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Jun 8, 2026
CompletionEst.
Jul 18, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301203
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Oct 21, 2025
Primary completion
Jun 8, 2026 (estimated)
Completion
Jul 18, 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

Yanru Yanru
Contact
yanru.yan@cplabpharma.com
+8618210654987

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion